- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01226537
Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
November 7, 2012 updated by: Hamad Medical Corporation
Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar.
It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy, cardiomyopathy, and severe vascular dysfunction.
The complications of diabetes are caused by either insulin deficiency (type 1 DM) or insulin resistance (type II DM).Unfortunately, effective and sustainable prevention programs of diabetes are limited, and treatment options for type II DM are restricted.
Current therapy is based upon control of blood glucose, cholesterol and triglycerides, primarily through insulin replacement in type I diabetes or oral hypoglycemic agents and/or insulin replacement in type II diabetes.
New therapies able to prevent vascular complications of diabetes are needed to decrease the occurrence of end organ damage and improve the quality of life of the people.
Safe and effective nutritional supplements that could be given along with the regular treatment of the patients that might reduce the need for insulin replacement therapy provide tighter glucose control and protect against oxidative stress and the vascular pathology associated with diabetes mellitus are the need of the hour.
Our hypothesis is that supplementation of Taurine in the diets of diabetic patients might reduce the dose or need for insulin replacement therapy and protect them against oxidative stress that is responsible for the complications of diabetes mellitus.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shajitha Thekkeveetil, PhD
- Phone Number: 00974-44395096
- Email: sveetil@hmc.org.qa
Study Contact Backup
- Name: Yousef Al Ansari, MD
- Phone Number: 00974-2112754
- Email: yalansari@hmc.org.qa
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or Female
- Above 18-65 Years of old
- Known diabetic patients with HbA1c>8.0%
- People who provide signed informed consent -
Exclusion Criteria:
- 1. Pregnancy 2. Diabetic patients with HbA1c <8.0 % 3. Recent or prospective surgical interventions 4. Complications of Type I and Type II DM, e.g., Active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. People who do not provide signed informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Diabetes Mellitus type 1 taurine
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg
Taurine capsules will be given twice per day for 6 months.
|
500 mg taurine capsules twice per day for 6 months
|
Placebo Comparator: Diabetes mellitus type 1 placebo
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg
Taurine capsules will be given twice per day for 6 months.
|
500 mg taurine capsules twice per day for 6 months
|
Active Comparator: Diabetes type 2 taurine
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg
Taurine capsules will be given twice per day for 6 months.
|
500 mg taurine capsules twice per day for 6 months
|
Placebo Comparator: Diabetes type 2 placebo
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg
Taurine capsules will be given twice per day for 6 months.
|
500 mg taurine capsules twice per day for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test
Time Frame: 9 months
|
500mg Taurine capsules will be given twice per day for 6 months.
After the medication, each month the following outcomes will be measured Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Anticipated)
November 1, 2013
Study Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
October 21, 2010
First Submitted That Met QC Criteria
October 21, 2010
First Posted (Estimate)
October 22, 2010
Study Record Updates
Last Update Posted (Estimate)
November 9, 2012
Last Update Submitted That Met QC Criteria
November 7, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT01225588
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on it is a Group of Metabolic Diseases in
-
Purdue UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedThe Null Hypothesis is That Food Rheology Will Have no Effect on These Indices | The Alternate Hypothesis is That Increased Mechanical Stimulation Will Result in Stronger Satiation/Satiety and Reduced Energy Intake | It is Hypothesized That the Effects of Mastication Will be Less Evident...United States
-
Cairo UniversityUnknownTeeth Size in a Group of Egyptian ChildrenEgypt
-
IRCCS Centro Neurolesi "Bonino-Pulejo"CompletedIt is Possible That Amadeo Will Guarantee a Greater Clinical Improvement as Compared to an Occupational Therapy Thanks to the Strengthening of Brain PlasticityItaly
-
Blood Donation Service Zurich, SRCUnknownGenetic Blood Group (bg) Polymorphism in U Negativity and St(a) of MNSsSwitzerland
-
Alvotech Swiss AGActive, not recruitingThis is a Phase Study Conducted in Healthy VolunteersSouth Africa
-
European Institute for Evidence Based Osteopathic...AvailableThe Focus of the Study is to Provide a Guideline on Osteopathic Approach in Treating Hospitalized Newborns.
-
Health NavigatorVastra Gotaland Region; Region Stockholm; Ostergotland County Council, Sweden; Uppsala... and other collaboratorsUnknownThe Focus is to Investigate Effect of a Case Management Interventions in Frequent Visitors to Emergency DepartmentsSweden
-
University of PennsylvaniaCompletedIn Need of a Pap Smear (Cervical Cancer Screening) | In Need of a Blood Pressure Check (Hypertension Screening) | In Need of a Cholesterol Test (Lipid Disorder Screening) | In Need of a Fasting Plasma Glucose Test (Diabetes)United States
-
Jinnah Sindh Medical UniversityAl Khidmat Hospital Nazimabad Karachi; Medics Laboratories (Pvt.) Ltd.CompletedThe Main Focus of This Study is to Evaluate the Safety of Zingiber Officinale L. Tablets as Hypolipidemic Agent in Hypertensive PatientsPakistan
-
Johannes Gutenberg University MainzUnknownFocus of the Study is to Evaluate a New Developed Deep-learning Computer-aided Detection System in Combination With LCI for Colorectal Polyp DetectionGermany
Clinical Trials on Taurine
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Completed
-
Zhiming ZhuCompletedPrehypertensionChina
-
Ain Shams UniversityCompleted
-
University of Illinois at ChicagoNational Cancer Institute (NCI); Rush University Medical CenterActive, not recruitingColorectal CancerUnited States
-
Hospital de Clinicas de Porto AlegreRecruitingDiabetes Mellitus, Type 2Brazil
-
Cambridge Health AllianceStanley Medical Research Institute; Mclean HospitalTerminated
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Not yet recruiting
-
University Health Network, TorontoRecruitingThalassemia MajorCanada
-
Ain Shams UniversityCompleted